The Pharmaceutical Industry in the Public Debate
There has been criticism in the media of the innovative pharmaceutical industry, i.e. pharmaceutical manufacturers that develop new drugs. The criticism relates to the low added value of new drugs, high prices, large profits and high marketing costs. There has also been a good deal of discussion of the way in which the pharmaceutical industry handles research findings and promotes products. The question is, to what extent is the criticism based on fact?
The trade association of the innovative pharmaceutical industry (Nefarma) and the Pharmaceutical Committee of the American Chamber of Commerce in the Netherlands (Amcham) asked SEO Economic Research to check the media statements against reality: what is true and what is not true?
Do you have any questions about this publication?
Feel free to contact Lucy Kok via e-mail or phone. She will respond to your questions as soon as possible.
"*" indicates required fields